Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
358
-
Total 13F shares, excl. options
-
111M
-
Shares change
-
+3.2M
-
Total reported value, excl. options
-
$16.5B
-
Value change
-
+$493M
-
Put/Call ratio
-
0.89
-
Number of buys
-
204
-
Number of sells
-
-128
-
Price
-
$148.11
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2020
428 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2020.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 358 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111M shares
of 132M outstanding shares and own 84.73% of the company stock.
Largest 10 shareholders include FMR LLC (17.1M shares), VANGUARD GROUP INC (10.9M shares), WELLINGTON MANAGEMENT GROUP LLP (10.5M shares), BlackRock Inc. (9.12M shares), BAILLIE GIFFORD & CO (8.65M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.27M shares), Dodge & Cox (4.7M shares), STATE STREET CORP (2.79M shares), JPMORGAN CHASE & CO (2.22M shares), and RTW INVESTMENTS, LP (1.68M shares).
This table shows the top 358 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.